541 related articles for article (PubMed ID: 25236915)
1. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
[TBL] [Abstract][Full Text] [Related]
3. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
4. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.
Sil Oh E; Ok Kim C; Kim KH; Kim YN; Kim C; Lee JI; Park MS
Clin Ther; 2014 Jul; 36(7):1064-71. PubMed ID: 25047497
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
9. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
10. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
[TBL] [Abstract][Full Text] [Related]
11. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
[TBL] [Abstract][Full Text] [Related]
12. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
13. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
[TBL] [Abstract][Full Text] [Related]
14. Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Zhi J; Zhai S; Georgy A; Liang Z; Boldrin M
J Clin Pharmacol; 2016 May; 56(5):548-54. PubMed ID: 26272330
[TBL] [Abstract][Full Text] [Related]
15. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
18. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
[TBL] [Abstract][Full Text] [Related]
19. Effects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men.
Nguyen D; Mizne S
Adv Ther; 2017 Oct; 34(10):2371-2385. PubMed ID: 29022184
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]